ERNA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ERNA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Eterna Therapeutics's annualized net income for the quarter that ended in Mar. 2024 was $-26.59 Mil. Eterna Therapeutics's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was $-0.59 Mil. Therefore, Eterna Therapeutics's annualized ROE % for the quarter that ended in Mar. 2024 was N/A%.
The historical rank and industry rank for Eterna Therapeutics's ROE % or its related term are showing as below:
During the past 4 years, Eterna Therapeutics's highest ROE % was -95.20%. The lowest was -840.08%. And the median was -216.45%.
The historical data trend for Eterna Therapeutics's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eterna Therapeutics Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
ROE % | -95.20 | -739.05 | -130.70 | -302.20 |
Eterna Therapeutics Quarterly Data | |||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
ROE % | Get a 7-Day Free Trial | -222.34 | -320.68 | -602.15 | -849.42 | - |
For the Biotechnology subindustry, Eterna Therapeutics's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Eterna Therapeutics's ROE % distribution charts can be found below:
* The bar in red indicates where Eterna Therapeutics's ROE % falls into.
Eterna Therapeutics's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as
ROE % | = | Net Income (A: Dec. 2023 ) | / | ( (Total Stockholders Equity (A: Dec. 2022 ) | + | Total Stockholders Equity (A: Dec. 2023 )) | / count ) |
= | -21.668 | / | ( (12.107 | + | 2.233) | / 2 ) | |
= | -21.668 | / | 7.17 | ||||
= | -302.20 % |
Eterna Therapeutics's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as
ROE % | = | Net Income (Q: Mar. 2024 ) | / | ( (Total Stockholders Equity (Q: Dec. 2023 ) | + | Total Stockholders Equity (Q: Mar. 2024 )) | / count ) |
= | -26.588 | / | ( (2.233 | + | -3.412) | / 2 ) | |
= | -26.588 | / | -0.5895 | ||||
= | N/A % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.
* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.
Eterna Therapeutics (NAS:ERNA) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
ROE % | (Q: Mar. 2024 ) | ||||
= | Net Income | / | Total Stockholders Equity | ||
= | -26.588 | / | -0.5895 | ||
= | (Net Income / Revenue ) | * | (Revenue / Total Assets) | * | (Total Assets / Total Stockholders Equity) |
= | (-26.588 / 0.188) | * | (0.188 / 49.3945) | * | (49.3945 / -0.5895) |
= | Net Margin % | * | Asset Turnover | * | Equity Multiplier |
= | -14142.55 % | * | 0.0038 | * | N/A |
= | ROA % | * | Equity Multiplier | ||
= | -53.74 % | * | N/A | ||
= | N/A % |
With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.
The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:
ROE % | (Q: Mar. 2024 ) | ||||||||
= | Net Income | / | Total Stockholders Equity | ||||||
= | -26.588 | / | -0.5895 | ||||||
= | (Net Income / Pre-Tax Income) | * | (Pre-Tax Income / Operating Income) | * | (Operating Income / Revenue) | * | (Revenue / Total Assets) | * | (Total Assets / Total Stockholders Equity) |
= | (-26.588 / -26.572) | * | (-26.572 / -23.148) | * | (-23.148 / 0.188) | * | (0.188 / 49.3945) | * | (49.3945 / -0.5895) |
= | Tax Burden | * | Interest Burden | * | Operating Margin % | * | Asset Turnover | * | Equity Multiplier |
= | 1.0006 | * | 1.1479 | * | -12312.77 % | * | 0.0038 | * | N/A |
= | N/A % |
Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income. * In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Thank you for viewing the detailed overview of Eterna Therapeutics's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Dorothy J Clarke | director | C/O ETERNA THERAPEUTICS INC., 1035 CAMBRIDGE STREET, STE. 18A, CAMBRIDGE MA 02141 |
Charles Cherington | 10 percent owner | ONE BOW STREET, CAMBRIDGE MA 02138 |
Brant Binder | director | C/O TRUST CO OF THE SWEST, 200 PARK AVE SUITE 220, NEW YORK NY 01066 |
Richard W Wagner | director | C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER ST, WALTHAM MA 02451 |
Curtis W Huft | 10 percent owner | 4510 LAMESA HWY, SNYDER TX 79549 |
Freebird Partners Lp | 10 percent owner | 2800 POST OAK BLVD., SUITE 2000, HOUSTON TX 77056 |
Freebird Investments Llc | 10 percent owner | 2800 POST OAK BLVD., SUITE 2000, HOUSTON TX 77056 |
John D Halpern | 10 percent owner | |
Nicholas Jason Singer | director | 1395 BRICKELL AVENUE, SUITE 800, MIAMI FL 33131 |
William A. Wexler | director | 12 GILL STREET, SUITE 4650, WOBURN MA 01801 |
Gregory Fiore | director | 10355 SCIENCE CENTER DRIVE, SUITE 150, SAN DIEGO CA 92121 |
Andrew C. Jackson | officer: Chief Financial Officer | 11988 EL CAMINO REAL STE. 650, SAN DIEGO CA 92130 |
Matthew Angel | officer: Interim President and CEO | 10531 4S COMMONS DRIVE, SUITE 160-550, SAN DIEGO CA 92127 |
Heather B Redman | director | TWO NORTH NINTH STREET, ALLENTOWN PA 18101 |
Erin S. Enright | director | 666 PLAINSBORO ROAD, PLAINSBORO NJ 08536 |
From GuruFocus
By PurpleRose PurpleRose • 07-26-2022
By GuruFocusNews GuruFocusNews • 06-26-2022
By GuruFocusNews GuruFocusNews • 06-20-2022
By GlobeNewswire GlobeNewswire • 06-17-2022
By GuruFocusNews GuruFocusNews • 07-07-2022
By Marketwired • 09-05-2023
By sperokesalga sperokesalga • 05-02-2023
By sperokesalga sperokesalga • 05-04-2023
By sperokesalga sperokesalga • 03-28-2023
By GuruFocusNews GuruFocusNews • 06-27-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.